Triple negative breast cancer: 5 years follow-up

Article
First Online:
Received:
Revised:
Accepted:

Abstract

Objective

The aim of the study was to investigate the long-term therapeutic effects of triple negative breast cancers (TNBCs) and find a standardized treatment.

Methods

The clinical data and survival status of 69 patients with TNBC were collected, who were treated from 2003 to 2007 at Chongqing Cancer Institute, China.

Results

Median observation for 61 months showed the local recurrence rate was 13.0% (9/69), the overall survival (OS) rate was 76.8% (53/69) and the disease free survival (DFS) rate was 59.4% (41/69). Log-rank univariate survival analysis showed the OS and DFS rates of TNBCs with axillary lymph node metastasis were 38.1% and 23.8%, respectively, and the OS and DFS rates of triple negative breast cancer with axillary lymph node non-metastasis were 93.8% and 75.0%, respectively. There were significant differences comparing with two groups. Indictor analysis of age, menstruation status, tumor size, TNM stage, histological type, neoadjuvant chemotherapy and p53 did not show any prognostic influence.

Conclusion

The axillary nodes metastasis is associated with DFS and OS in triple negative breast cancers. Cisplatin-based chemotherapy may be good choice for triple negative breast cancers with metastasis or local recurrence, who received Anthracycline and Taxane-based chemotherapy. Targeted therapies strategies such as EGFR-targeted therapy may be necessary.

Key words

breast cancer triple negative survival analysis 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Brenton JD, Carey LA, Ahmed AA, et al. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol, 2005, 23: 7350–7360.PubMedCrossRefGoogle Scholar
  2. 2.
    Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer, 2007, 109: 25–32.PubMedCrossRefGoogle Scholar
  3. 3.
    Harris LN, Broadwater G, Lin NU, et al. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res, 2006, 8: R66.PubMedCrossRefGoogle Scholar
  4. 4.
    Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res, 2007, 13: 4429–4434.PubMedCrossRefGoogle Scholar
  5. 5.
    Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer, 2007, 109: 1721–1728.PubMedCrossRefGoogle Scholar
  6. 6.
    Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol, 2006, 24: 5652–5657.PubMedCrossRefGoogle Scholar
  7. 7.
    Cao H, Yan MS, Wang SB, et al. Clinical characteristics and prognosis of triple-negative breast cancer. Chinese-German J Clin Oncol, 2009, 8: 471–475.CrossRefGoogle Scholar
  8. 8.
    Cho EY, Chang MH, Choi YL, et al. Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC). Cancer Chemother Pharmacol, 2010 Dec 18 [Epub ahead of print].Google Scholar
  9. 9.
    Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res, 2007, 9: R65.PubMedCrossRefGoogle Scholar
  10. 10.
    Tan DS, Marchió C, Jones RL, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracyclinetreated patients. Breast Cancer Res Treat, 2008, 111: 27–44.PubMedCrossRefGoogle Scholar
  11. 11.
    James CR, Quinn JE, Mullan PB, et al. BRCA1, a potential predictive biomarker in the treatment of breast cancer. Oncologist, 2007, 12: 142–150.PubMedCrossRefGoogle Scholar
  12. 12.
    Ezz Elarab LR, Mahdy ME, Karim KA. BRCA1 and EGFR as prognostic biomarkers in triple negative metastatic breast cancer patients treated with cisplatin plus docetaxel. Chinese-German J Clin Oncol, 2010, 9: 700–707.CrossRefGoogle Scholar
  13. 13.
    Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 2006, 295: 2492–2502.PubMedCrossRefGoogle Scholar
  14. 14.
    Yuli C, Shao N, Rao R, et al. BRCA1a has antitumor activity in TN breast, ovarian and prostate cancers. Oncogene, 2007, 26: 6031–6037.PubMedCrossRefGoogle Scholar
  15. 15.
    Yang C, Wang ZY, Yao Y, et al. The effect and side effects of Gemcitabine plus Vinorelbine in patients with triple-negative metastatic breast cancer. Chinese-German J Clin Oncol, 2009, 8: 557–560.CrossRefGoogle Scholar
  16. 16.
    Siziopikou KP, Cobleigh M. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast, 2007, 16: 104–107.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  1. 1.Department of Breast SurgeryChongqing Cancer InstituteChongqingChina

Personalised recommendations